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Randomised controlled trials, when appropriately de-
signed, conducted, and reported, represent the gold stan-
dard in evaluating healthcare interventions. However,
randomised trials can yield biased results if they lack meth-
odological rigour [1]. To assess a trial accurately, readers of
a published report need complete, clear, and transparent in-
formation on its methodology and findings. Unfortunately,
attempted assessments frequently fail because authors of
many trial reports neglect to provide lucid and complete de-
scriptions of that critical information [2e4].
That lack of adequate reporting fuelled the development
of the original CONSORT (Consolidated Standards of Re-
porting Trials) statement in 1996 [5] and its revision five
years later [6e8]. While those statements improved the re-
porting quality for some randomised controlled trials
[9,10], many trial reports still remain inadequate [2]. Fur-
thermore, new methodological evidence and additionalThe CONSORT statement is used worldwide to improve the reporting
of randomised controlled trials. Kenneth Schulz and colleagues describe
the latest version, CONSORT 2010, which updates the reporting guideline
based on new methodological evidence and accumulating experience.
In order to encourage dissemination of the CONSORT 2010 Statement,
this article is freely accessible on bmj.com and will also be published in the
Lancet, Obstetrics andGynecology, PloSMedicine, Annals of InternalMed-
icine, Open Medicine, Journal of Clinical Epidemiology, BMC Medicine,
and Trials. The authors jointly hold the copyright for this article. For details
on further use, see the CONSORt website (www.consort-statement.org).
This is an open-access article distributed under the terms of the Crea-
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with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and
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doi: 10.1016/j.jclinepi.2010.02.005experience has accumulated since the last revision in
2001. Consequently, we organised a CONSORT Group
meeting to update the 2001 statement [6e8]. We introduce
here the result of that process, CONSORT 2010.2. Intent of CONSORT 2010
The CONSORT 2010 Statement is this paper including
the 25 item checklist in Table 1 and the flow diagram. It
provides guidance for reporting all randomised controlled
trials, but focuses on the most common design typedindi-
vidually randomised, two group, parallel trials. Other trial
designs, such as cluster randomised trials and non-
inferiority trials, require varying amounts of additional in-
formation. CONSORT extensions for these designs
[11,12], and other CONSORT products, can be found
through the CONSORT website (www.consort-statement.
org). Along with the CONSORT statement, we have up-
dated the explanation and elaboration article [13], which
explains the inclusion of each checklist item, provides
methodological background, and gives published examples
of transparent reporting (Fig. 1).
Flow diagram of the progress through the phases of
a parallel randomised trial of two groups (that is, enrol-
ment, intervention allocation, follow-up, and data analysis).
Diligent adherence by authors to the checklist items fa-
cilitates clarity, completeness, and transparency of report-
ing. Explicit descriptions, not ambiguity or omission, best
serve the interests of all readers. Note that the CONSORT
2010 Statement does not include recommendations for de-
signing, conducting, and analysing trials. It solely addresses
the reporting of what was done and what was found.
Nevertheless, CONSORT does indirectly affect design
and conduct. Transparent reporting reveals deficiencies in re-
search if they exist. Thus, investigators who conduct inade-
quate trials, but who must transparently report, should not. All rights reserved.
Table 1
CONSORT 2010 checklist of information to include when reporting a randomised trial*
Section/Topic Item No Checklist item Reported on page No
Title and abstract
1a Identification as a randomised trial in the title
1b Structured summary of trial design, methods, results, and conclusions (for specific
guidance see CONSORT for abstracts [21,31])
Introduction
Background and objectives 2a Scientific background and explanation of rationale
2b Specific objectives or hypotheses
Methods
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio
3b Important changes to methods after trial commencement (such as eligibility criteria),
with reasons
Participants 4a Eligibility criteria for participants
4b Settings and locations where the data were collected
Interventions 5 The interventions for each group with sufficient details to allow replication, including
how and when they were actually administered
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures,
including how and when they were assessed
6b Any changes to trial outcomes after the trial commenced, with reasons
Sample size 7a How sample size was determined
7b When applicable, explanation of any interim analyses and stopping guidelines
Randomisation:
Sequence generation 8a Method used to generate the random allocation sequence
8b Type of randomisation; details of any restriction (such as blocking and block size)
Allocation concealment
mechanism
9 Mechanism used to implement the random allocation sequence (such as sequentially
numbered containers), describing any steps taken to conceal the sequence until
interventions were assigned
Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who
assigned participants to interventions
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants,
care providers, those assessing outcomes) and how
11b If relevant, description of the similarity of interventions
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses
Results
Participant flow (a diagram is
strongly recommended)
13a For each group, the numbers of participants who were randomly assigned, received
intended treatment, and were analysed for the primary outcome
13b For each group, losses and exclusions after randomisation, together with reasons
Recruitment 14a Dates defining the periods of recruitment and follow-up
14b Why the trial ended or was stopped
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and
whether the analysis was by original assigned groups
Outcomes and estimation 17a For each primary and secondary outcome, results for each group, and the estimated
effect size and its precision (such as 95% confidence interval)
17b For binary outcomes, presentation of both absolute and relative effect sizes is
recommended
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted
analyses, distinguishing pre-specified from exploratory
Harms 19 All important harms or unintended effects in each group (for specific guidance see
CONSORT for harms[28])
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant,
multiplicity of analyses
Generalisability 21 Generalisability (external validity, applicability) of the trial findings
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering
other relevant evidence
Other information
Registration 23 Registration number and name of trial registry
Protocol 24 Where the full trial protocol can be accessed, if available
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders
* We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration [13] for important clarifications
on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials [11], non-inferiority and equivalence trials [12],
non-pharmacological treatments [32], herbal interventions [33], and pragmatic trials [34]. Additional extensions are forthcoming: for those and for up to date
references relevant to this checklist, see www.consort-statement.org.
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lation of their trial’s inadequacies. That emerging reality
should provide impetus to improved trial design and conduct
in the future, a secondary indirect goal of our work. More-
over, CONSORT can help researchers in designing their trial.3. Background to CONSORT
Efforts to improve the reporting of randomised con-
trolled trials accelerated in the mid-1990s, spurred partly
by methodological research. Researchers had shown for
many years that authors reported such trials poorly, and em-
pirical evidence began to accumulate that some poorly con-
ducted or poorly reported aspects of trials were associated
with bias [14]. Two initiatives aimed at developing report-
ing guidelines culminated in one of us (DM) and Drum-
mond Rennie organising the first CONSORT statement in
1996 [5]. Further methodological research on similar topics
reinforced earlier findings[15] and fed into the revision of
2001 [6e8]. Subsequently, the expanding body of method-
ological research informed the refinement of CONSORT
2010. More than 700 studies comprise the CONSORT data-
base (located on the CONSORT website), which provides
the empirical evidence to underpin the CONSORT
initiative.
Indeed, CONSORT Group members continually monitor
the literature. Information gleaned from these efforts pro-
vides an evidence base on which to update the CONSORT
statement. We add, drop, or modify items based on that ev-
idence and the recommendations of the CONSORT Group,
an international and eclectic group of clinical trialists, stat-
isticians, epidemiologists, and biomedical editors. The
CONSORT Executive (KFS, DGA, DM) strives for a bal-
ance of established and emerging researchers. The member-
ship of the group is dynamic. As our work expands in
response to emerging projects and needed expertise, we in-
vite new members to contribute. As such, CONSORT con-
tinually assimilates new ideas and perspectives. That
process informs the continually evolving CONSORT
statement.Over time, CONSORT has garnered much support. More
than 400 journals, published around the world and in many
languages, have explicitly supported the CONSORT state-
ment. Many other healthcare journals support it without
our knowledge. Moreover, thousands more have implicitly
supported it with the endorsement of the CONSORT state-
ment by the International Committee of Medical Journal
Editors (www.icmje.org). Other prominent editorial groups,
the Council of Science Editors and the World Association
of Medical Editors, officially support CONSORT. That sup-
port seems warranted: when used by authors and journals,
CONSORT seems to improve reporting [9].4. Development of CONSORT 2010
Thirty one members of the CONSORT 2010 Group met
in Montebello, Canada, in January 2007 to update the 2001
CONSORT statement. In addition to the accumulating
evidence relating to existing checklist items, several new
issues had come to prominence since 2001. Some partici-
pants were given primary responsibility for aggregating
and synthesising the relevant evidence on a particular
checklist item of interest. Based on that evidence, the group
deliberated the value of each item. As in prior CONSORT
versions, we kept only those items deemed absolutely fun-
damental to reporting a randomised controlled trial. More-
over, an item may be fundamental to a trial but not
included, such as approval by an institutional ethical review
board, because funding bodies strictly enforce ethical re-
view and medical journals usually address reporting ethical
review in their instructions for authors. Other items may
seem desirable, such as reporting on whether on-site mon-
itoring was done, but a lack of empirical evidence or any
consensus on their value cautions against inclusion at this
point. The CONSORT 2010 Statement thus addresses the
minimum criteria, although that should not deter authors
from including other information if they consider it
important.
After the meeting, the CONSORT Executive convened
teleconferences and meetings to revise the checklist. After
seven major iterations, a revised checklist was distributed
to the larger group for feedback. With that feedback, the ex-
ecutive met twice in person to consider all the comments
and to produce a penultimate version. That served as the ba-
sis for writing the first draft of this paper, which was then
distributed to the group for feedback. After consideration
of their comments, the executive finalised the statement.
The CONSORT Executive then drafted an updated ex-
planation and elaboration manuscript, with assistance from
other members of the larger group. The substance of the
2007 CONSORT meeting provided the material for the up-
date. The updated explanation and elaboration manuscript
was distributed to the entire group for additions, deletions,
and changes. That final iterative process converged to the
CONSORT 2010 Explanation and Elaboration [13].
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The revision process resulted in evolutionary, not revolu-
tionary, changes to the checklist (Table 1), and the flow di-
agram was not modified except for one word (Fig. 1).
Moreover, because other reporting guidelines augmenting
the checklist refer to item numbers, we kept the existing
items under their previous item numbers except for some
renumbering of items 2 to 5. We added additional items ei-
ther as a sub-item under an existing item, an entirely new
item number at the end of the checklist, or (with item 3)
an interjected item into a renumbered segment. We have
summarised the noteworthy general changes in Box 1 and
specific changes in Box 2. The CONSORTwebsite contains
a side by side comparison of the 2001 and 2010 versions.6. Implications and limitations
We developed CONSORT 2010 to assist authors in writing
reports of randomised controlled trials, editors and peer re-
viewers in reviewing manuscripts for publication, and readers
in critically appraising published articles. The CONSORT
2010 Explanation and Elaboration provides elucidation and
context to the checklist items. We strongly recommend using
the explanation and elaboration in conjunctionwith the check-
list to foster complete, clear, and transparent reporting and aid
appraisal of published trial reports.
CONSORT 2010 focuses predominantly on the two
group, parallel randomised controlled trial, which accounts
for over half of trials in the literature [2]. Most of the items
from the CONSORT 2010 Statement, however, pertain to
all types of randomised trials. Nevertheless, some types
of trials or trial situations dictate the need for additional in-
formation in the trial report. When in doubt, authors, edi-
tors, and readers should consult the CONSORT website
for any CONSORT extensions, expansions (amplifications),
implementations, or other guidance that may be relevant.
The evidence based approach we have used for CON-
SORT also served as a model for development of other re-
porting guidelines, such as for reporting systematic reviews
and meta-analyses of studies evaluating interventions [16],
diagnostic studies [17], and observational studies [18]. TheBox 1. Noteworthy general changes in CONSORT 2010 S
 We simplified and clarified the wording, such as in items 1
 We improved consistency of style across the items by remo
 We enhanced specificity of appraisal by breaking some item
plete a CONSORT checklist indicating where in the manus
checklist noted pragmatic difficulties when an item comp
eligibility of participants and the settings and locations of
provide a page number for that item on the checklist, bu
example, and not reported the settings and locations. CON
provide page numbers in the checklist for both eligibility aexplicit goal of all these initiatives is to improve reporting.
The Enhancing the Quality and Transparency of Health Re-
search (EQUATOR) Network will facilitate development of
reporting guidelines and help disseminate the guidelines:
www.equator-network.org provides information on all re-
porting guidelines in health research.
With CONSORT 2010, we again intentionally declined
to produce a rigid structure for the reporting of randomised
trials. Indeed, SORT [19] tried a rigid format, and it failed
in a pilot run with an editor and authors [20]. Consequently,
the format of articles should abide by journal style, editorial
directions, the traditions of the research field addressed,
and, where possible, author preferences. We do not wish
to standardise the structure of reporting. Authors should
simply address checklist items somewhere in the article,
with ample detail and lucidity. That stated, we think that
manuscripts benefit from frequent subheadings within the
major sections, especially the methods and results sections.
CONSORT urges completeness, clarity, and transpar-
ency of reporting, which simply reflects the actual trial
design and conduct. However, as a potential drawback,
a reporting guideline might encourage some authors to
report fictitiously the information suggested by the guid-
ance rather than what was actually done. Authors, peer re-
viewers, and editors should vigilantly guard against that
potential drawback and refer, for example, to trial proto-
cols, to information on trial registers, and to regulatory
agency websites. Moreover, the CONSORT 2010 State-
ment does not include recommendations for designing
and conducting randomised trials. The items should elicit
clear pronouncements of how and what the authors did,
but do not contain any judgments on how and what the
authors should have done. Thus, CONSORT 2010 is not
intended as an instrument to evaluate the quality of a trial.
Nor is it appropriate to use the checklist to construct
a ‘‘quality score.’’
Nevertheless, we suggest that researchers begin trials
with their end publication in mind. Poor reporting allows
authors, intentionally or inadvertently, to escape scrutiny
of any weak aspects of their trials. However, with wide
adoption of CONSORT by journals and editorial groups,
most authors should have to report transparently alltatement
, 8, 10, 13, 15, 16, 18, 19, and 21
ving the imperative verbs that were in the 2001 version
s into sub-items. Many journals expect authors to com-
cript the items have been addressed. Experience with the
rised multiple elements. For example, item 4 addresses
data collection. With the 2001 version, an author could
t might have reported only eligibility in the paper, for
SORT 2010 relieves obfuscations and forces authors to
nd settings
Box 2. Noteworthy specific changes in CONSORT 2010 Statement
Item 1b (title and abstract)dWe added a sub-item on providing a structured summary of trial design, methods, results,
and conclusions and referenced the CONSORT for abstracts article [21]
Item 2b (introduction)dWe added a new sub-item (formerly item 5 in CONSORT 2001) on ‘‘Specific objectives or
hypotheses’’
Item 3a (trial design)dWe added a new item including this sub-item to clarify the basic trial design (such as parallel
group, crossover, cluster) and the allocation ratio
Item 3b (trial design)dWe added a new sub-item that addresses any important changes to methods after trial
commencement, with a discussion of reasons
Item 4 (participants)dFormerly item 3 in CONSORT 2001
Item 5 (interventions)dFormerly item 4 in CONSORT 2001. We encouraged greater specificity by stating that
descriptions of interventions should include ‘‘sufficient details to allow replication’’ [3]
Item 6 (outcomes)dWe added a sub-item on identifying any changes to the primary and secondary outcome (endpoint)
measures after the trial started. This followed from empirical evidence that authors frequently provide analyses of out-
comes in their published papers that were not the prespecified primary and secondary outcomes in their protocols, while
ignoring their prespecified outcomes (that is, selective outcome reporting) [4,22]. We eliminated text on any methods
used to enhance the quality of measurements
Item 9 (allocation concealment mechanism)dWe reworded this to include mechanism in both the report topic and the
descriptor to reinforce that authors should report the actual steps taken to ensure allocation concealment rather than
simply report imprecise, perhaps banal, assurances of concealment
Item 11 (blinding)dWe added the specification of how blinding was done and, if relevant, a description of the simi-
larity of interventions and procedures. We also eliminated text on ‘‘how the success of blinding (masking) was as-
sessed’’ because of a lack of empirical evidence supporting the practice as well as theoretical concerns about the
validity of any such assessment [23,24]
Item 12a (statistical methods)dWe added that statistical methods should also be provided for analysis of secondary
outcomes
Sub-item 14b (recruitment)dBased on empirical research, we added a sub-item on ‘‘Why the trial ended or was
stopped’’ [25]
Item 15 (baseline data)dWe specified ‘‘A table’’ to clarify that baseline and clinical characteristics of each group are
most clearly expressed in a table
Item 16 (numbers analysed)dWe replaced mention of ‘‘intention to treat’’ analysis, a widely misused term, by a more
explicit request for information about retaining participants in their original assigned groups [26]
Sub-item 17b (outcomes and estimation)dFor appropriate clinical interpretability, prevailing experience suggested the
addition of ‘‘For binary outcomes, presentation of both relative and absolute effect sizes is recommended’’ [27]
Item 19 (harms)dWe included a reference to the CONSORT paper on harms [28]
Item 20 (limitations)dWe changed the topic from ‘‘Interpretation’’ and supplanted the prior text with a sentence
focusing on the reporting of sources of potential bias and imprecision
Item 22 (interpretation)dWe changed the topic from ‘‘Overall evidence.’’ Indeed, we understand that authors should be
allowed leeway for interpretation under this nebulous heading. However, the CONSORT Group expressed concerns that
conclusions in papers frequently misrepresented the actual analytical results and that harms were ignored or marginal-
ised. Therefore, we changed the checklist item to include the concepts of results matching interpretations and of
benefits being balanced with harms
Item 23 (registration)dWe added a new item on trial registration. Empirical evidence supports the need for trial
registration, and recent requirements by journal editors have fostered compliance [29]
Item 24 (protocol)dWe added a new item on availability of the trial protocol. Empirical evidence suggests that authors
often ignore, in the conduct and reporting of their trial, what they stated in the protocol [4,22]. Hence, availability of the
protocol can instigate adherence to the protocol before publication and facilitate assessment of adherence after
publication
Item 25 (funding)dWe added a new item on funding. Empirical evidence points toward funding source sometimes
being associated with estimated treatment effects [30]
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wards well conducted trials and penalises poorly conducted
trials. Thus, investigators should understand the CONSORT
2010 reporting guidelines before starting a trial as a further
incentive to design and conduct their trials according to rig-
orous standards.
CONSORT 2010 supplants the prior version published
in 2001. Any support for the earlier version accumulated
from journals or editorial groups will automatically extend
to this newer version, unless specifically requested other-
wise. Journals that do not currently support CONSORT
may do so by registering on the CONSORT website. If
a journal supports or endorses CONSORT 2010, it should
cite one of the original versions of CONSORT 2010, the
CONSORT 2010 Explanation and Elaboration, and the
CONSORT website in their ‘‘Instructions to authors.’’ We
suggest that authors who wish to cite CONSORT should
cite this or another of the original journal versions of CON-
SORT 2010 Statement, and, if appropriate, the CONSORT
2010 Explanation and Elaboration [13]. All CONSORT
material can be accessed through the original publishing
journals or the CONSORT website. Groups or individuals
who desire to translate the CONSORT 2010 Statement into
other languages should first consult the CONSORT policy
statement on the website.
We emphasise that CONSORT 2010 represents an
evolving guideline. It requires perpetual reappraisal and,
if necessary, modifications. In the future we will further re-
vise the CONSORT material considering comments, criti-
cisms, experiences, and accumulating new evidence. We
invite readers to submit recommendations via the CON-
SORT website.
Author contributions: KFS, DM, and DGA participated
in meetings and regular conference calls, planned the CON-
SORT 2007 meeting at Montebello, developed the agenda,
prepared background research, identified and invited partic-
ipants, contributed to the CONSORT meeting, drafted the
manuscript, and, after critical review by the CONSORT
Group, finalised the text of the manuscript. Members of
the CONSORT Group attended the meeting, except for
those noted below, and provided input on and review of
the revised checklist and text of this article. Some members
also prepared background material.
The CONSORT Group contributors to CONSORT 2010:
DG Altman, Centre for Statistics in Medicine, University of
Oxford; Virginia Barbour, PLoS Medicine; Jesse A Berlin,
Johnson & Johnson Pharmaceutical Research and Develop-
ment, USA; Isabelle Boutron, University Paris 7 Denis Di-
derot, Assistance Publique des Ho^pitaux de Paris,
INSERM, France; PJ Devereaux, McMaster University,
Canada; Kay Dickersin, Johns Hopkins Bloomberg School
of Public Health, USA; Diana Elbourne, London School of
Hygiene & Tropical Medicine; Susan Ellenberg, University
of Pennsylvania School of Medicine, USA; Val Gebski,
University of Sydney, Australia; Steven Goodman, Journal
of the Society for Clinical Trials, USA; Peter C Gøtzsche,Nordic Cochrane Centre, Denmark; Trish Groves, BMJ;
Steven Grunberg, American Society of Clinical Oncology,
USA; Brian Haynes, McMaster University, Canada; Sally
Hopewell, Centre for Statistics in Medicine, University of
Oxford; Astrid James, Lancet; Peter Juhn, Johnson & John-
son, USA; Philippa Middleton, University of Adelaide,
Australia; Don Minckler, University of California Irvine,
USA; D Moher, Ottawa Methods Centre, Clinical Epidemi-
ology Program, Ottawa Hospital Research Institute,
Canada; Victor M Montori, Knowledge and Encounter
Research Unit, Mayo Clinic College of Medicine, USA;
Cynthia Mulrow, Annals of Internal Medicine, USA; Stuart
Pocock, London School of Hygiene & Tropical Medicine;
Drummond Rennie, JAMA, USA; David L Schriger, Annals
of Emergency Medicine, USA; KF Schulz, Family Health
International, USA; Iveta Simera, EQUATOR Network;
Elizabeth Wager, Sideview.
Contributors to CONSORT 2010 who did not attend the
Montebello meeting: Mike Clarke, UK Cochrane Centre;
Gordon Guyatt, McMaster University, Canada.
Funding: We received financial support from United
Kingdom National Institute for Health Research and the
Medical Research Council; Canadian Institutes of Health
Research; Presidents Fund, Canadian Institutes of Health
Research; Johnson & Johnson; BMJ; and the American So-
ciety for Clinical Oncology. DGA is supported by Cancer
Research UK, DM by a University of Ottawa Research
Chair, and KFS by Family Health International. None of
the sponsors had any involvement in the planning, execu-
tion, or writing of the CONSORT documents. Additionally,
no funder played a role in drafting the manuscript.
Competing interests: Uniform disclosure of potential
conflicts of interest: all authors have completed the ICMJE
unified competing interest form at www.icmje.org/coi_
disclosure.pdf (available from the corresponding author)
and declare (1) DM received grants for this work from
Johnson & Johnson, BMJ, and American Society for Clin-
ical Oncology; KFS and DGA received support for travel to
meetings for this work from Johnson & Johnson, BMJ, and
American Society for Clinical Oncology; (2) KFS and DA
had travel expenses reimbursed by the EQUATOR Net-
work; KFS has received honoraria for delivering educa-
tional presentations for the American Board of Obstetrics
and Gynecology Foundation for Excellence in Women’s
Health Care, Ortho-McNeil Janssen Scientific Affairs, and
the American College of Obstetrics and Gynecology; and
has done consultancy for Wyeth. All authors also declare
(3) no spouses, partners, or children with relationships with
commercial entities that might have an interest in the sub-
mitted work; (4) no non-financial interests that may be rel-
evant to the submitted work.References
[1] Ju¨ni P, Altman DG, Egger M. Systematic reviews in health care: as-
sessing the quality of controlled clinical trials. BMJ 2001;323:42e6.
840 K.F. Schulz et al. / Journal of Clinical Epidemiology 63 (2010) 834e840[2] Chan AW, Altman DG. Epidemiology and reporting of randomised
trials published in PubMed journals. Lancet 2005;365:1159e62.
[3] Glasziou P, Meats E, Heneghan C, Shepperd S. What is missing from
descriptions of treatment in trials and reviews? BMJ 2008;336:
1472e4.
[4] Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E, et al.
Systematic review of the empirical evidence of study publication bias
and outcome reporting bias. PLoS ONE 2008;3:e3081.
[5] Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Im-
proving the quality of reporting of randomized controlled trials. The
CONSORT statement. JAMA 1996;276:637e9.
[6] Moher D, Schulz KF, Altman DG. The CONSORT statement: revised
recommendations for improving the quality of reports of
parallel-group randomised trials. Lancet 2001;357:1191e4.
[7] Moher D, Schulz KF, Altman DG. The CONSORT statement: revised
recommendations for improving the quality of reports of
parallel-group randomized trials. Ann Intern Med 2001;134:657e62.
[8] Moher D, Schulz KF, Altman D. The CONSORT statement: revised
recommendations for improving the quality of reports of
parallel-group randomized trials. JAMA 2001;285:1987e91.
[9] Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, et al.
Does the CONSORT checklist improve the quality of reports of rand-
omised controlled trials? A systematic review. Med J Aust 2006;185:
263e7.
[10] Hopewell S, Dutton S, Yu L-M, Chan A-W, Altman DG. The quality
of reports of randomised trials in 2000 and 2006: a comparative study
of articles indexed by PubMed. BMJ 2010;340:c723.
[11] Campbell MK, Elbourne DR, Altman DG. CONSORT statement: ex-
tension to cluster randomised trials. BMJ 2004;328:702e8.
[12] Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. Report-
ing of noninferiority and equivalence randomized trials: an extension
of the CONSORT statement. JAMA 2006;295:1152e60.
[13] Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC,
Devereaux PJ, et al. CONSORT 2010 Explanation and Elaboration:
updated guidelines for reporting parallel group randomised trials.
BMJ 2010;340:c869.
[14] Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of
bias. Dimensions of methodological quality associated with estimates
of treatment effects in controlled trials. JAMA 1995;273:408e12.
[15] Moher D, Pham B, Jones A, Cook DJ, Jadad AR, MoherM, et al. Does
quality of reports of randomised trials affect estimates of intervention
efficacy reported in meta-analyses? Lancet 1998;352:609e13.
[16] Moher D, Liberati A, Tetzlaff J, Altman DGfor the PRISMA Group.
Preferred reporting items for systematic reviews and meta-analyses:
the PRISMA statement. BMJ 2009;339:b2535.
[17] Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP,
Irwig LM, et al. Towards complete and accurate reporting of studies
of diagnostic accuracy: the STARD initiative. BMJ 2003;326:41e4.
[18] von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC,
Vandenbroucke JPfor the STROBE Initiative. Strengthening thereporting of observational studies in epidemiology (STROBE) state-
ment: guidelines for reporting observational studies. BMJ 2007;335:
806e8.
[19] Standards of Reporting Trials Group. A proposal for structured re-
porting of randomized controlled trials. JAMA 1994;272:1926e31.
[20] Rennie D. Reporting randomized controlled trials. An experiment
and a call for responses from readers. JAMA 1995;273:1054e5.
[21] Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG,
et al. CONSORT for reporting randomised trials in journal and con-
ference abstracts. Lancet 2008;371:281e3.
[22] Chan AW, Hro´bjartsson A, Haahr MT, Gøtzsche PC, Altman DG.
Empirical evidence for selective reporting of outcomes in random-
ized trials: comparison of protocols to published articles. JAMA
2004;291:2457e65.
[23] Sackett DL. Commentary: Measuring the success of blinding in
RCTs: don’t, must, can’t or needn’t? Int J Epidemiol 2007;36:664e5.
[24] Schulz KF, Grimes DA. Blinding in randomised trials: hiding who
got what. Lancet 2002;359:696e700.
[25] Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH,
Briel M, et al. Randomized trials stopped early for benefit: a system-
atic review. JAMA 2005;294:2203e9.
[26] Hollis S, Campbell F. What is meant by intention to treat analysis?
Survey of published randomised controlled trials. BMJ 1999;319:
670e4.
[27] Nuovo J, Melnikow J, Chang D. Reporting number needed to treat
and absolute risk reduction in randomized controlled trials. JAMA
2002;287:2813e4.
[28] Ioannidis JP, Evans SJ, Gøtzsche PC, O’Neill RT, Altman DG,
Schulz K, et al. Better reporting of harms in randomized trials: an ex-
tension of theCONSORT statement.Ann InternMed2004;141:781e8.
[29] De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R,
et al. Clinical trial registration: a statement from the International
Committee of Medical Journal Editors. Lancet 2004;364:911e2.
[30] Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical indus-
try sponsorship and research outcome and quality: systematic review.
BMJ 2003;326:1167e70.
[31] Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG,
et al. CONSORT for reporting randomized controlled trials in journal
and conference abstracts: explanation and elaboration. PLoS Med
2008;5:e20.
[32] Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending
the CONSORT statement to randomized trials of nonpharmacologic
treatment: explanation and elaboration. Ann Intern Med 2008;148:
295e309.
[33] Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C.
Reporting randomized, controlled trials of herbal interventions: an
elaborated CONSORT statement. Ann Intern Med 2006;144:364e7.
[34] Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S,
Haynes B, et al. Improving the reporting of pragmatic trials: an exten-
sion of the CONSORT statement. BMJ 2008;337:a2390.
